131 related articles for article (PubMed ID: 18484647)
1. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
Jonasch E; Stadler WM; Bukowski RM; Hayes TG; Varadhachary A; Malik R; Figlin RA; Srinivas S
Cancer; 2008 Jul; 113(1):72-7. PubMed ID: 18484647
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of oral talactoferrin alfa in refractory solid tumors.
Hayes TG; Falchook GF; Varadhachary GR; Smith DP; Davis LD; Dhingra HM; Hayes BP; Varadhachary A
Invest New Drugs; 2006 May; 24(3):233-40. PubMed ID: 16193240
[TBL] [Abstract][Full Text] [Related]
3. Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors.
Hayes TG; Falchook GS; Varadhachary A
Invest New Drugs; 2010 Apr; 28(2):156-62. PubMed ID: 19238327
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Parikh PM; Vaid A; Advani SH; Digumarti R; Madhavan J; Nag S; Bapna A; Sekhon JS; Patil S; Ismail PM; Wang Y; Varadhachary A; Zhu J; Malik R
J Clin Oncol; 2011 Nov; 29(31):4129-36. PubMed ID: 21969509
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
6. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.
Motzer RJ; Hutson TE; Olsen MR; Hudes GR; Burke JM; Edenfield WJ; Wilding G; Agarwal N; Thompson JA; Cella D; Bello A; Korytowsky B; Yuan J; Valota O; Martell B; Hariharan S; Figlin RA
J Clin Oncol; 2012 Apr; 30(12):1371-7. PubMed ID: 22430274
[TBL] [Abstract][Full Text] [Related]
9. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
13. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.
Kankuri M; Pelliniemi TT; Pyrhönen S; Nikkanen V; Helenius H; Salminen E
Cancer; 2001 Aug; 92(4):761-7. PubMed ID: 11550145
[TBL] [Abstract][Full Text] [Related]
14. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.
Bukowski R; Ernstoff MS; Gore ME; Nemunaitis JJ; Amato R; Gupta SK; Tendler CL
J Clin Oncol; 2002 Sep; 20(18):3841-9. PubMed ID: 12228203
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.
Molina AM; Feldman DR; Ginsberg MS; Kroog G; Tickoo SK; Jia X; Georges M; Patil S; Baum MS; Reuter VE; Motzer RJ
Invest New Drugs; 2012 Feb; 30(1):335-40. PubMed ID: 20711632
[TBL] [Abstract][Full Text] [Related]
16. Talactoferrin immunotherapy in metastatic renal cell carcinoma: a case series of four long-term survivors.
Lewis MA; Hayes TG
J Clin Med Res; 2011 Feb; 3(1):47-51. PubMed ID: 22043271
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Gore ME; Szczylik C; Porta C; Bracarda S; Bjarnason GA; Oudard S; Hariharan S; Lee SH; Haanen J; Castellano D; Vrdoljak E; Schöffski P; Mainwaring P; Nieto A; Yuan J; Bukowski R
Lancet Oncol; 2009 Aug; 10(8):757-63. PubMed ID: 19615940
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma.
Iwamoto K; Ishihara H; Takagi T; Kondo T; Yoshida K; Iizuka J; Tanabe K
Med Oncol; 2018 Apr; 35(6):78. PubMed ID: 29687160
[TBL] [Abstract][Full Text] [Related]
20. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
Shi HZ; Tian J; Chen X; Wang D; Li CL
Clin Genitourin Cancer; 2017 Feb; 15(1):139-144. PubMed ID: 27338518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]